https://www.selleckchem.com/pr....oducts/pha-848125.ht
Several laboratory tests related to the liver function also revealed a similar decrease at the end of the DAA treatment. The analysis of MID-NET data provides useful information on drug safety assessment of real-world patients. The results of this study imply that fluctuation of the liver function test results may relate to the fluctuation of blood coagulability in patients on both DAA and warfarin. This study contributes to a deeper understanding of the usefulness and limitations of real-world data in MID-NET for regulatory purposes